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in the mouse carcinoma after treatment with RT + CTLA-4 
blockade. Significant changes in TCR repertoire were also 
seen in peripheral blood of responding patients, supporting 
the hypothesis that RT can convert the irradiated tumor into 
an in situ vaccine.  
Immunogenic cell death is induced by radiation in a dose-
dependent way, with higher ablative single doses being more 
effective in vitro (Golden et al., OncoImmunology 2014). 
However, in vivo the interaction between the dying cancer 
cells and the pre-existing immune microenvironment 
determines the ability of RT to prime effective anti-tumor T 
cell responses. For instance, we have shown that the number 
of DCs available in the tumor and draining lymph nodes to 
uptake and present the antigens released by RT is a critical 
determinant of the magnitude of the immune response 
elicited (Pilones et al., J Immuntother Cancer 2014). We have 
recently found that canonical pathways mediating the 
induction of type I interferon responses in epithelial cells 
during viral infection are induced by fractionated but not 
single dose RT. RT-induced cancer cell intrinsic interferon-I 
production enhanced DCs infiltration and was required for 
development of tumor-specific T cells capable of rejecting 
not only the irradiated tumor but also non-irradiated 
metastases (abscopal effect). This explains, at least in part, 
the synergy of fractionated RT regimens (8GyX3 or 6GyX5), 
but not a single ablative RT dose of 20 Gy, with anti-CTLA-4 
in achieving abscopal responses against poorly immunogenic 
carcinomas (Dewan et al., Clin Cancer Res 2009). In addition, 
we have shown that immunosuppressive mediators such as 
TGF-beta, which is released in its active form by RT-
generated ROS, need to be neutralized to improve DC 
maturation and activation of T cells capable of rejecting the 
tumor (Vanpouille-Box et al., Cancer Res 2015).  
Overall, optimal RT regimens combined with targeting of 
dominant immune suppressive pathways enable RT use as a 
simple, widely available tool for patient and tumor-specific 
in situ vaccination.  
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Recent clinical trials revealed the impressive efficacy of 
immunological checkpoint blockade in different types of 
metastatic cancers. Such data underscore that 
immunotherapy is one of the most promising strategies for 
cancer treatment. In addition, preclinical studies provide 
evidence that chemotherapy and radiotherapy have the 
ability to stimulate the immune system, resulting in anti-
tumor immune responses that contribute to clinical efficacy 
of these agents. These observations raise the hypothesis that 
the next step for cancer treatment is the combination of 
cytotoxic agents and immunotherapies. This presentation will 
discuss the immune-mediated effects of anticancer agents 
and their clinical relevance, the biological features of 
immune checkpoint blockers and finally, the rationale for 
novel therapeutic strategies combining anticancer agents and 
immune checkpoint blockers. 
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The evolution of radiation oncology is based on the increasing 
integration of imaging data into the design of highly 
personalized cancer treatments.  
Technologically advanced image-guided delivery techniques 
have made modern radiotherapy treatment extremely 
flexible in term of optimal sparing of the organs at risk and 
shaping different prescribed target doses to tumor volumes 
delineated on the basis of functional imaging information.  
In the last 10 years a remarkable development of more 
sensitive and specific signals (quantitative dynamic contrast-
enhanced CT and MRI; diffusion MRI, specific PET tracers, 
multi-parametric MRI/PET, etc) have contributed to the 
prescription and design of radiation treatment plan.  
The main contribution of new imaging modalities can be 
summarized:  
- Improved delineation of target and normal structures (new 
hybrid imaging devices offer co-registration of anatomical, 
functional and molecular information); a further refinement 
of this approach is the possibility to shape the dose gradually 
according to the functional parameters (dose painting);  
- Adaptation, the radiation technique defined at planning 
simulation can often require modification not only due to the 
changes in patient anatomy but because of early variations of 
certain imaging related parameters surrogates of treatment 
outcome.  
- Predictive biomarkers, the use of more advanced image 
analysis methods (texture feature parameters) could be a 
surrogate of important tumor characteristics and have a 
higher predictive and prognostic power than simpler numeric 
approaches;  
- Radiomics, the extraction of large amount from diagnostic 
medical images may be used to underlying molecular and 
genetic characteristics and this genetic profile may change 
over time because of therapy.  
Despite the multiple benefits that the quantitative imaging 
can offer for radiation therapy improvement, there are a 
number of technical challenges and organisational issues that 
need to be solved before its fruitful integration into RT 
treatment planning process.  
The main aspects covered by this lecture will be:  
- Standardized procedures for acquisition, reconstruction and 
elaboration of PET data set;  
- Methods for delineation of the PET-related biological target 
volume (BTV). 
- Data acquisition and processing techniques used to manage 
respiratory motion in PET/CT studies; the use of personalized 
motion information for target volume definition. 
- A procedure to improve target volume definition when using 
contrast enhanced 4D-CT imaging in pancreatic carcinoma.  
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Pubmed references, presentations and posters during a lot of 
Conferences (ESTRO, EFOMP, ESMRMB, EANM,...) are 
introducing a lot of biological and functional imaging for 
radiotherapy applications: MRI, PET, SPECT, functional CT 
are able to support radiation therapy for target and Organ of 
Risk definition. Looking at the EUROPEAN GUIDELINES ON 
MEDICAL PHYSICS EXPERT (RP 174) the competence on 
biological and functional imaging is not specific item into RT 
skill and competences. We can find the key activities of MPEs 
inside the following: Diag.& Therap. NM Internal Dosimetry 
Measurements( K23: Explain methods for determining 
